Format

Send to

Choose Destination
PLoS One. 2014 Apr 15;9(4):e93441. doi: 10.1371/journal.pone.0093441. eCollection 2014.

Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth.

Author information

1
Departments of Surgery and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, United States of America.
2
Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina, United States of America.
3
b3 bio, Inc. Research Triangle Park, North Carolina, United States of America.
4
Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina, United States of America; b3 bio, Inc. Research Triangle Park, North Carolina, United States of America.

Abstract

β-arrestins, ubiquitous cellular scaffolding proteins that act as signaling mediators of numerous critical cellular pathways, are attractive therapeutic targets because they promote tumorigenesis in several tumor models. However, targeting scaffolding proteins with traditional small molecule drugs has been challenging. Inhibition of β-arrestin 2 with a novel aptamer impedes multiple oncogenic signaling pathways simultaneously. Additionally, delivery of the β-arrestin 2-targeting aptamer into leukemia cells through coupling to a recently described cancer cell-specific delivery aptamer, inhibits multiple β-arrestin-mediated signaling pathways known to be required for chronic myelogenous leukemia (CML) disease progression, and impairs tumorigenic growth in CML patient samples. The ability to target scaffolding proteins such as β-arrestin 2 with RNA aptamers may prove beneficial as a therapeutic strategy.

HIGHLIGHTS:

An RNA aptamer inhibits β-arrestin 2 activity.Inhibiting β-arrestin 2 impedes multiple tumorigenic pathways simultaneously.The therapeutic aptamer is delivered to cancer cells using a cell-specific DNA aptamer.Targeting β-arrestin 2 inhibits tumor progression in CML models and patient samples.

PMID:
24736311
PMCID:
PMC3988186
DOI:
10.1371/journal.pone.0093441
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center